Get Premium to unlock powerful stock data
NAS:INCY (USA)  
Incyte Corp logo

Incyte Corp

$ 77.67 +1.7 (+2.24%) 08:08 PM EST
P/E:
18.49
P/B:
4.45
Market Cap:
$ 17.20B
Enterprise V:
$ 14.70B
Volume:
1.29M
Avg Vol (2M):
1.43M
Also Trade In:
Volume:
1.29M
Market Cap $:
17.20B
PE Ratio:
18.49
Avg Vol (2-Month):
1.43M
Enterprise Value $:
14.70B
PB Ratio:
4.45
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Financials (Next Earnings Date:2022-08-03 Est.)

INCY's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:INCY

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3,114.784
EPS (TTM) ($) 4.2
Beta 0.72
Volatility % 25.74
14-Day RSI 59.11
14-Day ATR ($) 2.223524
20-Day SMA ($) 73.255
12-1 Month Momentum % -10.76
52-Week Range ($) 61.91 - 84.86
Shares Outstanding (Mil) 221.51

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Incyte Corp Filings

Document Form Filing Date
No Filing Data

Headlines

See More